Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in Pediatric Heart Failure Patients With Left Ventricular Systolic Dysfunction
NCT07192952Phase 3Recruiting
- Sponsor
- Bayer
- Start
- Jun 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of finerenone in heart failure (HF), left ventricular systolic dysfunction (LVSD), sponsored by Bayer. Started Jun 2026; status: recruiting.
02
Drugs
finerenone
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NCT07192952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192952.